Insider · CIK 0001507650

Zanganeh Mahkam

CIK 0001507650 Name as filed on the most recent filing

Filed as Zanganeh Mahkam (8)· Zanganeh Maky (17)

59 transaction lines · from 25 filings · filed 2013-12-18 to 2026-06-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

59 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-06-12 P, Open-market purchase Summit Therapeutics Inc.SMMT 49,987,200, acquired Open Form 4 filing 0001507650-26-000007
2026-06-04 P, Open-market purchase Summit Therapeutics Inc.SMMT 1,460,000, acquired Open Form 4 filing 0001507650-26-000005
2025-10-21 P, Open-market purchase Summit Therapeutics Inc.SMMT 499,983, acquired Open Form 4 filing 0001507650-25-000003
2025-09-11 P, Open-market purchase Summit Therapeutics Inc.SMMT 90,350, acquired Open Form 4 filing 0001599298-25-000143
2025-09-10 P, Open-market purchase Summit Therapeutics Inc.SMMT 5,894,406, acquired Open Form 4 filing 0001599298-25-000143
2024-03-27 P, Open-market purchase Summit Therapeutics Inc.SMMT 3 lines 298,594, acquired Open Form 4 filing 0001599298-24-000047
2024-03-26 P, Open-market purchase Summit Therapeutics Inc.SMMT 112,500, acquired Open Form 4 filing 0001599298-24-000047
2023-12-12 P, Open-market purchase Summit Therapeutics Inc.SMMT 10,350, acquired Open Form 4 filing 0001599298-23-000103
2023-03-08 P, Open-market purchase Summit Therapeutics Inc.SMMT 2 lines 24,703,396, acquired Open Form 4 filing 0001387131-23-003381
2023-03-08 P, Open-market purchase Summit Therapeutics Inc.SMMT 3 lines 24,703,396, acquired Open Form 4 filing 0001599298-23-000028
2022-08-16 P, Open-market purchase Summit Therapeutics Inc.SMMT 3 lines 5,634,858, acquired Open Form 4 filing 0001387131-22-008886
2021-05-12 P, Open-market purchase Summit Therapeutics Inc.SMMT 2,038,763, acquired Open Form 4 filing 0000921895-21-001334
2020-06-23 P, Open-market purchase Pulse Biosciences, Inc.PLSE 12,767, acquired Open Form 4 filing 0001209191-20-038948
2020-06-17 P, Open-market purchase Pulse Biosciences, Inc.PLSE 55,730, acquired Open Form 4 filing 0001209191-20-037928
2017-12-13 P, Open-market purchase Pulse Biosciences, Inc.PLSE 26,378, acquired Open Form 4 filing 0001209191-17-065914
2017-12-12 P, Open-market purchase Pulse Biosciences, Inc.PLSE 23,979, acquired Open Form 4 filing 0001209191-17-065525
2017-12-11 P, Open-market purchase Pulse Biosciences, Inc.PLSE 68,289, acquired Open Form 4 filing 0001209191-17-065525
2017-09-18 P, Open-market purchase Pulse Biosciences, Inc.PLSE 116,791, acquired Open Form 4 filing 0001209191-17-053234
2017-09-14 P, Open-market purchase Pulse Biosciences, Inc.PLSE 2 lines 280,879, acquired Open Form 4 filing 0001209191-17-053234
2017-08-03 P, Open-market purchase Pulse Biosciences, Inc.PLSE 3 lines 481,332, acquired Open Form 4 filing 0001209191-17-047762
2017-08-02 P, Open-market purchase Pulse Biosciences, Inc.PLSE 208,469, acquired Open Form 4 filing 0001209191-17-047762
2017-05-11 P, Open-market purchase Pulse Biosciences, Inc.PLSE 312,540, acquired Open Form 4 filing 0001209191-17-031672
2017-05-10 P, Open-market purchase Pulse Biosciences, Inc.PLSE 108,545, acquired Open Form 4 filing 0001209191-17-031672
2017-05-09 P, Open-market purchase Pulse Biosciences, Inc.PLSE 680,500, acquired Open Form 4 filing 0001209191-17-031672
2017-03-20 P, Open-market purchase Pulse Biosciences, Inc.PLSE 2 lines 67,120, acquired Open Form 4 filing 0001209191-18-021891
2017-03-20 P, Open-market purchase Pulse Biosciences, Inc.PLSE 3 lines 210,665, acquired Open Form 4 filing 0001209191-17-021889
2017-03-17 P, Open-market purchase Pulse Biosciences, Inc.PLSE 47,860, acquired Open Form 4 filing 0001209191-18-021891
2017-03-17 P, Open-market purchase Pulse Biosciences, Inc.PLSE 215,004, acquired Open Form 4 filing 0001209191-17-021889
2017-02-15 P, Open-market purchase Pulse Biosciences, Inc.PLSE 75,342, acquired Open Form 4 filing 0001209191-18-021891
2017-02-15 P, Open-market purchase Pulse Biosciences, Inc.PLSE 155,649, acquired Open Form 4 filing 0001209191-17-013103
2017-02-14 P, Open-market purchase Pulse Biosciences, Inc.PLSE 115,131, acquired Open Form 4 filing 0001209191-18-021891
2017-02-13 P, Open-market purchase Pulse Biosciences, Inc.PLSE 2 lines 33,466, acquired Open Form 4 filing 0001209191-18-021891
2015-03-11 S, Open-market sale Pharmacyclics IncPCYC 7,623,444, disposed Open Form 4 filing 0001209191-15-026712
2015-03-11 S, Open-market sale Pharmacyclics IncPCYC 7,623,444, disposed Open Form 4 filing 0001209191-15-026168
2014-11-12 S, Open-market sale Pharmacyclics IncPCYC 2 lines 818,216, disposed Open Form 4 filing 0001209191-14-068222

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director
O, Officer
Officer

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 46
  • Open-market sale 13
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Zanganeh Mahkam, insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001507650

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.